1. Wang, Ning, Zhu, Lingye, Wang, Liangxing, Shen, Zhifa, Huang, Xiaoying. 2022. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers. In Computational and structural biotechnology journal, 20, 3106-3119. doi:10.1016/j.csbj.2022.06.039. https://pubmed.ncbi.nlm.nih.gov/35782736/
2. Shi, Wengui, Zhang, Gengyuan, Ma, Zhijian, Sun, Hui, Jiao, Zuoyi. 2021. Hyperactivation of HER2-SHCBP1-PLK1 axis promotes tumor cell mitosis and impairs trastuzumab sensitivity to gastric cancer. In Nature communications, 12, 2812. doi:10.1038/s41467-021-23053-8. https://pubmed.ncbi.nlm.nih.gov/33990570/
3. Qi, Gonghua, Ma, Hanlin, Teng, Kai, Luo, Xia, Kong, Beihua. 2024. SHCBP1 promotes cisplatin resistance of ovarian cancer through AKT/mTOR/Autophagy pathway. In Apoptosis : an international journal on programmed cell death, 30, 83-98. doi:10.1007/s10495-024-02027-3. https://pubmed.ncbi.nlm.nih.gov/39397124/
4. Gu, Qianlin, Ma, Zhijian, Wang, Qiaoyan, Shi, Wengui, Jiao, Zuoyi. 2024. Knockout of Shcbp1 sensitizes immunotherapy by regulating α-SMA positive cancer-associated fibroblasts. In Molecular carcinogenesis, 63, 601-616. doi:10.1002/mc.23675. https://pubmed.ncbi.nlm.nih.gov/38169303/
5. Huang, Yufan, You, Maojin, Wu, Qingfeng, Guo, Fei, Lin, Wangchun. . SHCBP1 Is a Prognostic Biomarker Related to the Tumour Immune Microenvironment in Pan-Cancer. In Annals of clinical and laboratory science, 52, 904-917. doi:. https://pubmed.ncbi.nlm.nih.gov/36564070/
智鼠故事 
